GlassScriptPhysician profile
James P Amerena
NPI 1912981929
$4,808.37
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $948 · 2021: $1,349 · 2022: $811 · 2023: $769 · 2024: $15.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $784.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $937.19 | 2019-2023 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $816.90 | 2019-2024 | Ozempic, Rybelsus |
| Eisai INC. | $362.80 | 2020-2021 | |
| Allergan, INC. | $350.85 | 2019-2020 | |
| Pfizer INC. | $265.87 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $255.99 | 2019-2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $252.61 | 2019-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $246.56 | 2019-2023 | Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.51 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $190.21 | 2019-2022 | |
| Lilly USA, LLC | $163.23 | 2019-2023 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $143.37 | 2019-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $102.52 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $96.21 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $63.13 | 2022-2023 | Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $57.44 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $48.20 | 2021 | |
| Amarin Pharma, INC. | $46.73 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.93 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $36.30 | 2022 | |
| Medtronic, INC. | $34.88 | 2021-2023 | Vanta Adaptivestim |
| Esperion Therapeutics, INC. | $24.09 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $22.67 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.27 | 2022 | |
| Ironwood Pharmaceuticals, INC | $13.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Amerena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.